Introduction
============

The clinical course of patients after successful cardiopulmonary resuscitation (CPR) is often complicated by post-resuscitation disease, a condition of multiple life-threatening disorders related to whole-body ischemia and reperfusion syndrome \[[@B1],[@B2]\]. This phenomenon shares many features with severe sepsis, including a systemic inflammatory response with plasma cytokine elevation, coagulation abnormalities, and myocardial dysfunction \[[@B3]\]. Ischemia, reperfusion and hypoxia during or after CPR induce generalized tissue damage with release of reactive oxygen species and endothelial-leukocyte interaction and activation, resulting in increased microvascular permeability and, hence, in loss of endothelial integrity \[[@B2]\]. Several studies demonstrated an endothelial activation with a consecutive endothelial injury following cardiac arrest \[[@B4]-[@B6]\] and in models of ischemia and reperfusion \[[@B7],[@B8]\].

A new tool for evaluation of endothelial injury is detection of circulating endothelial cells (CECs): these cells detach from the intima monolayer in response to endothelial damage and become measurable in peripheral blood. Although CECs are rarely found in the blood of healthy individuals, raised numbers are present in patients with a wide variety of diseases involving the endothelium such as vasculitis \[[@B9]\], arterial occlusive disease \[[@B10]\], and cardiovascular disease \[[@B11]\]. There is a strong relation between CECs and endothelial dysfunction because numbers of CECs correlate with surrogate markers of disturbed endothelial function such as flow-mediated dilation and von Willebrand factor (vWF) \[[@B12]\]. Plasma vWF is one of the most established plasma surrogate markers of endothelial damage or dysfunction \[[@B13]\]. VWF antigen concentrations are elevated on the second day after CPR and seem to be an early predictor of outcome \[[@B14]\].

Additionally, there is an increase of endothelial microparticles (EMPs) in states of disturbed endothelial function. Microparticles are small shed membranous vesicles (\<1 μm) that are released from cells upon activation or during apoptosis. They reflect the state of their parental cells in amounts and phenotypes \[[@B15]\]. Microparticles have procoagulant properties, modulate endothelial function, and play a role in inflammatory processes \[[@B16]\]. EMPs were found to be elevated in peripheral blood of patients suffering from acute coronary syndrome \[[@B17]\], or peripheral arterial disease \[[@B18]\]. Circulating endothelial progenitor cells (EPCs) are capable of repairing damaged endothelium and furthermore contribute to re-endothelialization and neovascularization \[[@B19]\]. These cells are bone marrow-derived pluripotent vascular progenitor cells that home in on the sites of ischemia and vascular injury \[[@B20]\]. A decrease in EPC count in peripheral blood is associated with endothelial dysfunction \[[@B21]\]. Patients with coronary artery disease showed reduced levels of EPCs \[[@B22]\] and there was an inverse correlation of number of EPCs in the peripheral blood, increased atherosclerotic risk factors, and a higher cardiovascular morbidity and mortality \[[@B23]\].

In the present study, we hypothesize that endothelial injury takes place during and after CPR, which in turn may contribute to post-resuscitation disease. Therefore, the aim of the present study is to detect direct markers of endothelial damage such as CECs, EMPs and vWF, as well as markers of endothelial repair (EPCs) in peripheral blood of patients after successful CPR.

Materials and methods
=====================

Patients and blood sampling protocol
------------------------------------

After the approval of the ethics committee of our institution for both studies (EK-Freiburg 115/07), we first included 40 patients who underwent CPR after cardiac arrest in a prospective study to measure endothelial injury and compared them with 30 patients suffering from stable coronary artery diseases (CAD) and 9 healthy subjects. Subsequently, we prospectively included 15 resuscitated patients to detect endothelial repair. Nine CAD patients and five healthy subjects served as controls. As elevation of CECs, microparticles and EPCs have been described to increase in various malignancies and in severe sepsis, patients with malignant diseases and sepsis were excluded from the study \[[@B24]\]. Patients younger than 18 years and trauma patients were also excluded. Informed consent was obtained *post hoc*from patients surviving with good neurological outcome, or from their relatives in the case of nonsurviving patients. Informed consent was given by all patients in the control groups.

Using an arterial catheter, blood samples in resuscitated patients were collected immediately after admission to the ICU and a second sample was collected 24 hours after return to spontaneous circulation (ROSC) in the CEC and EMP study. EPC study samples were collected on the second day after ROSC. In control patients, blood was drawn from the arterial catheter immediately after percutaneous coronary intervention (PCI). On the second day after PCI and in controls who did not receive PCI, blood was drawn by venopuncture. Samples were drawn slowly, handled carefully and analyzed immediately after sampling. For vein puncture, we used a 21-gauge butterfly needle and discarded the first 7.5 mL.

Flow cytometric analysis was performed on a three-color flow cytometer (FACSCalibur™, BD Biosciences, San Jose, CA, USA) with individual settings for each antibody utilizing Cell Quest Pro™software (BD Biosciences, San Jose, CA, USA).

Detection of CECs by flow cytometry analysis
--------------------------------------------

For measurement of CECs, 2.5 mL of blood was collected in EDTA tubes. CECs were detected by a commercially available detection kit (Biocytex, Marseille, France) according to the manufacturer\'s instructions. CECs were isolated from whole blood by ferromagnetic separation and stained with fluorochrome-labelled monoclonal antibodies (mAb), namely anti-human fluorescein isothiocyanate (FITC)-CD45 and anti-human PE-CD146 for cell detection or anti-human FITC-CD45 and anti-mouse PE-IgG serving as control, respectively. Tubes were analyzed by flow cytometry analysis. Cells larger than the counting beads and with at least the granularity of lymphocytes were gated after identification on the forward/sideward scatter. In this gate, CECs were identified as positive for the specific marker CD146 (melanoma cell adhesion molecule (MCAM), a cell-adhesion molecule used as a marker for endothelial cell lineage) and negative for the hematopoietic marker CD45 (PTPRC, present on all differentiated hematopoietic cells; Figure [1](#F1){ref-type="fig"}). Samples were analyzed at a flow rate of 60 μl/min for 200 seconds.

![**Flow cytometric detection of circulating endothelial cells in peripheral blood**. Three-color flow cytometry evaluation of circulating endothelial cells (CECs). CD 146-positive and CD 45-negative cells were identified as CECs. In the panel, CEC appear on the upper left as a separate cell population (arrows).](cc9050-1){#F1}

Detection of activated EMPs by flow cytometry analysis
------------------------------------------------------

For analysis of EMP, blood was collected in citrated tubes and was centrifuged for 10 minutes at 240 g at room temperature. Supernatant was diluted 1:50 with Tyrode buffer, then incubated for 30 minutes at room temperature in the dark with fluorochrome-labelled anti-human RPE-E-selectin (Southern Biotech, Birmingham, AL, USA) to detect EMPs or anti-mouse PE-IgG (Beckman Coulter, Marseille, France) serving as controls. During incubation, the cytometer was rinsed with FacsFlow™(BD Biosciences, Erembodegem-Aalst, Belgium). After fixation of the tubes with 300 μL of CellFix™(BD Biosciences, Erembodegem-Aalst, Belgium), samples were ready to be analyzed by flow cytometry. Microparticles were gated by a size of less than 1 μm using beads (Biocytex, Marseille, France) with a defined size of 0.9 μm (Figures [2a](#F2){ref-type="fig"} and b). Subsequently, microparticles positive for E-selectin (CD62E), which originated from activated endothelial cells were identified as activated EMPs (Figure [2c](#F2){ref-type="fig"}). Samples were analyzed at a flow rate of 12 μl/min for 180 seconds.

![**Flow cytometric detection of endothelial microparticles in peripheral blood**. Three-color flow cytometry evaluation of endothelial microparticles (EMPs). **(a)**Detection of particles with a size of less than 1 μm by nano-beads, **(b)**then gating of microparticles in the lower right. **(c)**Events staining positive for the fluorochrome-labelled antibody directed against E-selectin (CD62E) were identified as EMPs. FSC, forward scatter; SSC, side scatter.](cc9050-2){#F2}

Detection of EPCs by flow cytometry analysis
--------------------------------------------

A 20 mL blood sample was used for enumeration of EPCs. Samples were collected in EDTA tubes and kept on ice at all times. Peripheral blood mononuclear cells were isolated by Ficoll density-gradient centrifugation at 4°C, resuspended in 1,000 μL of BSA 0.1% PBS and incubated for 10 minutes. After centrifugation at 1,000 rpm for five minutes at 4°C, the pellet was resuspended in 2 mL lysing buffer (constituting of NH~4~Cl, KHCO~3~and tetrasodium-EDTA) and incubated for 10 minutes. Following a further centrifugation at 1,000 rpm for five minutes at 4°C and discarding supernatant, the pellet was washed twice in PBS and resuspended in 100 μL PBS. Thereafter, samples were incubated for 30 minutes in the dark with the following fluorochrome-labelled mAbs: 10 μL of anti-human FITC-CD34 (BD Biosciences, San Jose, CA, USA), anti-human PE-AC133 (Miltenyi Biotec GmbH, Auburn, CA, USA), and anti-human RPE-vascular endothelial growth factor-receptor 2 (VEGF-R2) (R&D Systems, Minneapolis, MN, USA), or anti-mouse FITC-/PE-IgG (Beckman Coulter, Marseille, France). Having washed the pellet twice with PBS, it was resuspended in 500 μL CellFix™(BD Biosciences, Erembodegem-Aalst, Belgium). Thereafter, tubes were ready for flow cytometry analysis. We measured 10,000 events in a lymphocyte gate. Triple-positive cells were identified by the expression of VEGF-R2 within the double-positive CD34+/CD133+ population gated. The number of EPCs was expressed as percentage of triple-positive cells of all lymphocytes.

Measurement of vWF in resuscitated patients
-------------------------------------------

In resuscitated patients, analysis was accompanied by photometric measurement of plasma vWF levels in the central laboratory of the university hospital Freiburg. Levels were compared with normal values of our institutional laboratory.

Statistical analysis
--------------------

Data are presented as means with the standard error of the mean and compared by Student\'s t-tests and Chi-Quadrate tests. Correlations between selected variables were estimated by Spearman\'s rank correlation coefficient. All tests were two-sided and a level of *P*less than 0.05 was accepted as significant. Data was analyzed with SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Baseline characteristics
------------------------

In all resuscitated patients, overall duration of mechanical resuscitation varied from 5 to 120 minutes (mean 23.2 ± 2.7 minutes). The presenting initial rhythm was ventricular fibrillation or ventricular tachycardia in 58%, asystole or pulseless electrical activity in 42%. Fourty-two patients (76%) presented a presumable cardiac cause for cardiac arrest and 29 patients (53%) survived 10 days or more in the ICU (Table [1](#T1){ref-type="table"}).

###### 

Basic data of CPR and CAD patients

                                                                                 CPR group    CAD group    *P* value                                                 
  --------------------------------------------------- -------------------------- ------------ ------------ ---------------- ------------ ---------- ---------------- ---------------
  **Age**                                             (years)                    65.3 ± 2.2   66.8 ± 3.1   **65.7 ± 1.8**   64.9 ± 2.8   67 ± 4.3   **64.3 ± 2.3**   ***0.32/ns***
                                                                                                                                                                     
  **Gender**                                          Male                       32 (80%)     10 (67%)     **42 (76%)**     26 (87%)     6 (67%)    **32 (82%)**     ***0.63/ns***
                                                      Female                     8 (20%)      5 (33%)      **13 (24%)**     4 (13%)      3 (33%)    **7 (18%)**      
                                                                                                                                                                     
  **Location of CPR**                                 in-hospital                13 (33%)     2 (13%)      **15 (27%)**                                              
                                                      out-of-hospital            27 (67%)     13 (87%)     **40 (73%)**                                              
                                                                                                                                                                     
  **Duration of CPR**                                 (min)                      27.3 ± 3.5   12.3 ± 2     **23.2 ± 2.7**                                            
                                                                                                                                                                     
  **Initial rhythm**                                  VF/VT                      21 (52%)     11 (73%)     **32 (58%)**                                              
                                                      Asystole/PEA               19 (48%)     4 (27%)      **23 (42%)**                                              
                                                                                                                                                                     
  **Cause of cardiac arrest or hospital admission**   Cardiac                    29 (72%)     13 (87%)     **42 (76%)**     30 (100%)    8 (89%)    **38 (97%)**     ***0.11/ns***
                                                      Non-cardiac                11 (28%)     3 (20%)      **14 (24%)**     0 (0%)       1 (11%)    **1 (3%)**       
                                                                                                                                                                     
  **Coronary angiography**                                                       27 (68%)     14 (93%)     **41 (75%)**     21 (70%)     6 (66%)    **27 (69%)**     ***0.62/ns***
                                                                                                                                                                     
  **Outcome**                                         Survival \<10 days         21 (52%)     5 (33%)      **26 (47%)**     0 (0%)       0 (0%)     **0 (0%)**       
                                                      Survival ≥ 10 days         19 (48%)     10 (67%)     **29 (53%)**     30 (100%)    9 (100%)   **39 (100%)**    
                                                                                                                                                                     
  **Medication**                                      Vasopressors               32 (80%)     15 (100%)    **47 (85%)**     0 (0%)       0 (0%)     **0 (0%)**       
                                                      Statins                    14 (35%)     1 (7%)       **15 (27%)**     20 (67%)     3 (33%)    **23 (59%)**     ***\<0.05***
                                                                                                                                                                     
  **Consecutive organ failure**                       Acute heart failure        10 (25%)     3 (20%)      **13 (24%)**     0 (0%)       0 (0%)     **0 (0%)**       
                                                      Acute renal failure        9 (23%)      1 (7%)       **10 (18%)**     0 (0%)       0 (0%)     **0 (0%)**       
                                                      Acute liver failure        2 (1%)       0 (0%)       **2 (4%)**       0 (0%)       0 (0%)     **0 (0%)**       
                                                                                                                                                                     
  **Co-morbidities**                                  CAD                        26 (65%)     14 (93%)     **40 (73%)**     30 (100%)    7 (77%)    **37 (95%)**     ***0.09/ns***
                                                      PAD                        6 (15%)      5 (33%)      **11 (20%)**     10 (33%)     1 (11%)    **11 (28%)**     ***0.25/ns***
                                                      Congestive heart failure   6 (15%)      1 (7%)       **7 (13%)**      6 (20%)      3 (33%)    **9 (23%)**      ***0.10/ns***
                                                      Pulmonary disease          12 (30%)     3 (20%)      **15 (27%)**     6 (20%)      4 (44%)    **10 (26%)**     ***0.89/ns***
                                                      Renal insufficiency        20 (50%)     6 (40%)      **26 (47%)**     8 (27%)      4 (44%)    **12 (31%)**     ***0.07/ns***
                                                      Liver insufficiency        7 (18%)      1 (7%)       **8 (15%)**      3 (10%)      0 (0%)     **3 (8%)**       ***0.14/ns***
                                                                                                                                                                     
  **Cardiovascular risk factors**                     Hypertension               22 (55%)     4 (27%)      **26 (47%)**     17 (57%)     4 (44%)    **21 (54%)**     ***0.49/ns***
                                                      Diabetes                   11 (28%)     5 (33%)      **16 (29%)**     3 (10%)      1 (11%)    **4 (10%)**      ***\<0.05***
                                                      Hyperlipidemia             8 (20%)      1 (7%)       **9 (16%)**      15 (50%)     2 (22%)    **17 (44%)**     ***\<0.01***
                                                      Smoking                    8 (20%)      5 (33%)      **13 (24%)**     10 (33%)     4 (44%)    **14 (36%)**     ***0.12/ns***

Basic data of the resuscitation group, including initial rhythm, outcome, location, and duration of CPR, and comparison of clinical variables in the CPR and CAD group. Both groups are comparable in baseline variables including age, gender, probable cause of cardiac arrest/cause of hospital admission, incidence of CAD, coronary angiography, congestive heart failure, and other relevant secondary disorders. There are slight but significant differences in distribution of cardiovascular risk factors as well as co-medication with statins.

CAD, coronary artery disease; CEC, circulating endothelial cells; CPR, cardiopulmonary resuscitation; EMP, endothelial microparticles; EPC, endothelial progenitor cells; ns, not significant; PAD, peripheral artery disease; PEA, pulseless electrical activity; VF, ventricular fibrillation; VT, ventricular tachycardia.

As more of the CPR patients in the smaller EPC study population presented ventricular fibrillation or ventricular tachycardia as the initial rhythm compared with patients in the CEC and EMP study (87% vs. 67%), duration of CPR in the EPC study group was shorter (27.3 ± 3.5 minutes vs. 12.3 ± 2.0 minutes), and outcome was better (survival ≥10 days in 67% vs. 48% of patients). Patients in the EPC study were showing higher rates of out-of-hospital cardiac arrests (87% vs. 67%), and a lower incidence of acute renal failure (7% vs. 23%) compared with resuscitated patients in the CEC and EMP study (Table [1](#T1){ref-type="table"}).

Average time from ROSC to blood sampling was 2 hours 48 minutes ± 17 minutes in the CEC and EMP study. The second blood sample was collected 26 hours 45 minutes ± 1 hour 15 minutes after ROSC. Blood samples in the EPC study were collected on the second day after ROSC.

Comparing all patients in both studies, patients of the resuscitation and CAD group were comparable in baseline characteristics such as gender and age at time of investigation (65.7 ± 1.8 years in the resuscitation group vs. 64.3 ± 2.3 years in the control group; *P*= 0.32 not significant (ns)). Of the resuscitated patients, 73% were presenting significant CAD versus 95% of the control group. Most of the patients in both groups underwent coronary angiography (75% in the resuscitation group and 69% in the CAD group). There were differences in the cardiovascular risk profile of the two groups: CAD patients had a higher incidence of hyperlipidemia (16% vs. 44%; *P*\< 0.05) and a trend to a higher prevalence of CAD and, hence, more of them were treated with statins (27% vs. 59%; *P*\< 0.01). The groups had a comparable profile of secondary disorders including pulmonary disease, and renal and liver insufficiency (Table [1](#T1){ref-type="table"}).

All measurements were also performed in healthy controls (nine in the CEC and EMP study and five in the EPC study), taking no medication and carrying no cardiovascular risk. Age at time point of investigation in the two groups was 30.5 ± 1.1 years and 37 ± 7 years, respectively.

Detection of CECs by flow-cytometry analysis and correlation with duration of CPR
---------------------------------------------------------------------------------

After CPR, we found a highly increased number of CECs in resuscitated patients. The mean number of CECs was 4,494.1 ± 1,246 cells/mL in patients after CPR. The number of CECs in resuscitated patients was significantly higher than in patients with stable CAD (mean number 312.7 ± 41 cells/mL; *P*\< 0.005) and in healthy controls (mean number 47.5 ± 3.7 cells/mL; *P*\< 0.0005; Figure [3](#F3){ref-type="fig"}). Patients who underwent prolonged CPR of 30 minutes or longer showed substantially elevated levels of circulating endothelial cells (mean number 6,216.6 ± 2,057 cells/mL) compared with patients resuscitated less than 30 minutes (mean number 2,340.9 ± 703.5 cells/mL; *P*= 0.13; ns). As depicted in Figure [4](#F4){ref-type="fig"}, CEC counts showed a significantly positive correlation with duration of CPR (R^2^= 0.84; *P*\< 0.01; Figure [4](#F4){ref-type="fig"}).

![**Elevation of circulating endothelial cells in patients after CPR**. Levels of circulating endothelial cells (CEC) in peripheral blood obtained from healthy subjects, patients with coronary artery disease (CAD) and after cardiopulmonary resuscitation (CPR) for less than 30 minutes (CPR \<30 min) and longer than 30 minutes (CPR ≥30 min), and in all resuscitated patients (CPR all). The number of CEC in all resuscitated patients was significantly higher compared with those in both control groups. \*\*\* *P*\< 0.0005 versus control; \*\* *P*\< 0.005 versus control.](cc9050-3){#F3}

![**Positive correlation of CEC count with duration of CPR**. Correlation between circulating endothelial cell (CEC) counts and the duration of cardiopulmonary resuscitation (CPR) showing a significant positive correlation. The rising numbers of CEC in peripheral blood with longer duration of resuscitation suggest a greater extent of endothelial damage during ongoing CPR (correlation coefficient 0.84; *P*\< 0.01).](cc9050-4){#F4}

Detection of activated EMPs by flow cytometry analysis
------------------------------------------------------

As a second marker of endothelial injury, we investigated the presence of EMPs in the peripheral blood of resuscitated patients. Microparticles are characterized by size (that typically ranges from 0.1 to 1.0 μm) and exposure of antigens that reflect origin and activation state of the cells they originate from. Here, we chose E-selectin as a marker of endothelial cell activation. The mean number (31.2 ± 5.8 events/μL) was slightly increased immediately after CPR but did not differ significantly from CAD patients (mean number 19.7 ± 2.4 events/μL; *P*= 0.12) or healthy controls (mean number 15.0 ± 5.2 events/μL; *P*= 0.07). Twenty-four hours after ROSC, the mean numbers of EMPs (69.1 ± 12.4 events/μL) in resuscitated patients were significantly higher than in the CAD group (mean number 22.0 ± 3.0 events/μL; *P*\< 0.005) and in healthy subjects 15.4 ± 4.4 events/μL; *P*\< 0.001; Figure [5](#F5){ref-type="fig"}). In addition, in patients after successful resuscitation the number of EMPs increased significantly in the first 24 hours (*P*\< 0.01). In controls, there was no significant difference between numbers of EMPs in a follow up of 24 hours (CAD: *P*= 0.55; healthy: *P*= 0.95).

![**Elevated endothelial microparticles in patients after CPR**. Levels of endothelial microparticles (EMPs) in peripheral blood obtained immediately after restoration of cardiopulmonary resuscitation (CPR; left) and 24 hours after return to spontaneous circulation (right) from healthy subjects (white bars), patients with coronary artery disease (CAD; grey bars) and after CPR (black bars). The number of EMPs in resuscitated patients immediately after return to spontaneous circulation was slightly higher compared with both control groups, showing a significant difference compared with controls 24 hours after return to spontaneous circulation). There is a significant rise in EMPs when comparing the two points in time after return to spontaneous circulation in the resuscitation group, reflecting an ongoing endothelial damage in the first 24 hours after CPR. \*\*\* *P*\< 0.001 versus control; \*\* *P*\< 0.005 versus control; \* *P*\< 0.01 versus control; ns, statistically not significant versus control.](cc9050-5){#F5}

Nine of the patients included, who were pre-treated with statins, immediately showed slightly lower EMP counts (22.3 ± 5.7 vs. 41.3 ± 12.6 events/μL; *P*= 0.23) and 24 hours after ROSC (62.6 ± 19.9 vs. 81.1 ± 19.2 events/μL; *P*= 0.49) compared with those without statin pre-treatment.

Detection of EPC by flow cytometry analysis
-------------------------------------------

To assess vascular repair following endothelial injury in patients after CPR, circulating EPCs were measured in peripheral blood of resuscitated patients in a follow-up study. Percentage of circulating EPCs in resuscitated patients were significantly higher than in control patients (1.16 ± 0.41% of gated lymphocytes in patients after CPR versus 0.02 ± 0.01% of gated lymphocytes (*P*\< 0.005) in CAD and 0.04 ± 0.01% of gated lymphocytes (*P*\< 0.005) in healthy controls; Figure [6](#F6){ref-type="fig"}). EPCs were identified by flow cytometry analysis as cells positive for CD34 (expressed on developmentally early stem and progenitor cells), CD133 (a marker expressed on immature cells) and VEGF-R2 (receptor mediating almost all of the known cellular responses to VEGF and essential for engraftment of hematopoietic stem and progenitor cells).

![**Elevation of endothelial progenitor cells in patients after CPR**. Three-color flow cytometry evaluation of endothelial progenitor cells (EPCs) in healthy subjects (left), patients with coronary artery disease (CAD; middle) and after cardiopulmonary resuscitation (CPR; right). EPC count, expressed in percentage of gated lymphocytes, was significantly higher in resuscitated patients compared with both control groups, pointing to early onset of endothelial repair after CPR. \*\* *P*\< 0.005 versus control.](cc9050-6){#F6}

vWF levels in resuscitated patients and correlation with other markers
----------------------------------------------------------------------

Resuscitated patients showed significant elevated plasma levels of vWF immediately (296.5 ± 73.4%; *P*\< 0.05) and 24 hours after ROSC (304.4 ± 22.8%; *P*\< 0.001), compared with normal values of our institutional laboratory (50 to 160%), indicating endothelial damage or dysfunction. Furthermore, vWF levels in resuscitated patients correlated significantly with CEC count (R^2^= 0.77; *P*\< 0.05; Figure [7](#F7){ref-type="fig"}).

![**Positive correlation of CEC count with von Willebrand factor**. Positive correlation between circulating endothelial cell (CEC) counts and von Willebrand factor levels in resuscitated patients, underlining the reliability of CEC count in detection of endothelial damage (correlation coefficient 0.77; *P*\< 0.05).](cc9050-7){#F7}

Discussion
==========

The vascular endothelium lining the blood vessels is one of the most complex and sensible organ systems. Its integrity is an important precondition for a regular function of the circulatory system. The endothelium governs a host of fundamental physiologic functions: endothelial cells serve as signal transduction cells for a variety of chemical and mechanical stimuli, produce cytokines, or other paracrine signalling molecules, regulate leukocyte adhesion and migration, and maintain the balance between pro- and anticoagulant mechanisms \[[@B25],[@B26]\].

The data presented in this report show the occurrence of severe endothelial damage in patients after successful CPR, and in a follow-up study, of a subsequent endothelial regeneration. In summary, we found a rapid and severe increase in CECs directly after CPR and a delayed increase in EMPs. This was paralleled by elevated levels of vWF, immediately and 24 hours after ROSC, compared with normal values. We chose vWF to support the flow cytometric measurements by a conventional and well-established marker of disturbed endothelium \[[@B13]\]. As levels of vWF showed a positive correlation with CEC count in resuscitated patients, these data underline the reliability of CEC count in the detection of endothelial damage. These results indicate early endothelial damage and ongoing endothelial dysfunction detected by elevated CECs and EMPs in resuscitated patients compared with control groups. Furthermore, numbers of EPCs increased on the second day after ROSC, which points to an early initiation of endothelial regeneration. The direct comparison with patients with stable CAD undergoing coronary intervention excluded effects possibly caused by CAD or coronary intervention.

In this study we could also demonstrate a significant positive correlation between the CEC count and the duration of CPR. In the literature, a long period of ischemia and longer duration of resuscitation efforts are associated with poor outcome \[[@B27],[@B28]\], and the timing of the ischemic insult and the length of the reperfusion have been shown to correlate with endothelial dysfunction variables and biochemical or histological evidence for cellular damage \[[@B25],[@B29]\]. Therefore, the correlation described in this study might reflect a greater extent of endothelial damage occurring during longer periods of CPR. However, we have to state that this positive correlation is largely due to a small number of patients with a long duration of CPR with CEC values outside the data cloud.

After cardiac arrest and mechanical resuscitation, there is growing evidence for an ischemia and reperfusion syndrome resulting in several inflammation cascades, including activation of leucocytes \[[@B30]\], up-regulation of selectins \[[@B4],[@B6]\], and adhesion molecules \[[@B5],[@B31]\] on the surface of the endothelium. Adrie and colleagues reported a \'sepsis-like syndrome\' after resuscitation, with an increase in circulating interleukins, TNF, and a generalized systemic inflammatory response \[[@B3]\]. Researchers recently stated that an early toll-like receptor 4-induced vascular injury might be an important trigger of the systemic inflammatory response in resuscitated mice \[[@B32]\]. In analogy to the data obtained in our study, there are reports of elevated numbers of CECs in critically ill patients presenting with acute respiratory distress syndrome \[[@B33]\] and severe inflammatory disease conditions such as septic shock \[[@B34]\]. Hence, we excluded patients with septic shock from the study. The relatively few patients in the study with in-hospital arrests and the high percentage of patients with cardiac-related arrest suggest that most patients were not critically ill prior to cardiac arrest. Moreover, in critically ill patients, who did not undergo CPR, CEC counts were only slightly elevated (comparable with the levels of the CAD group; data not shown). Therefore, it seems to be unlikely that critical illness or ICU procedures themselves contribute to the elevation of CECs. The currently available data does not allow for a clear differentiation of whether the increase of CECs is the cause or effect of the inflammatory reaction taking place. The very early elevation of CECs to a vast extent after CPR might be an indicator that endothelial damage could be the initial step in post-resuscitation disease resulting in secondary inflammatory reactions. Conceivable triggers for endothelial damage might be hypoxia \[[@B30]\] or shear stress \[[@B35],[@B36]\]. Therefore, it seems possible that shear stress during mechanical chest compression or the action itself is another cause of enhanced detachment of CEC from the endothelial layer.

We obtained comparatively high absolute values of CECs in this study, compared with the literature. In our opinion this indicates massive endothelial damage after CPR that largely exceeds the values detected in other diseases described so far in the available literature. This underlines the severity of this life-threatening condition, associated with complete discontinuation of circulation and high mortality. On the other hand, CEC counts in the literature vary from 15 to 670 cells/mL in various disease states \[[@B33],[@B37]\], which points out the inhomogeneity of this relatively new method. Furthermore, different methodical approaches might change the absolute values.

Interestingly, and in contrast to the CECs, the number of EMPs in resuscitated patients rises further in the first 24 hours after ROSC, hence reflecting an ongoing process of endothelial damage. As EMPs are elevated in several systemic inflammatory diseases such as vasculitis \[[@B38]\] and sepsis \[[@B39]\], the noticeable increase in EMP numbers could be due to the systemic inflammatory response occurring after CPR maintaining endothelial injury. EMP may express adhesion molecules specific to mature endothelial cells, such as platelet-endothelial cell adhesion molecule-1 (CD31), VE-cadherin (CD144), or MCAM (CD146). Activation of endothelial cells with TNF-α induced the formation of EMPs \[[@B16]\] exposing adhesion-cell molecules, including E-selectin (CD62E) or intercellular adhesion molecule-1 (CD54). In this study, we measured activation-induced EMPs by detection of E-selectin-positive microparticles. A possible explanation for the ongoing endothelial injury in the post-resuscitation period could be ischemia and reperfusion during cardiac arrest and mechanical resuscitation.

Interestingly, patients treated with statins prior to cardiac arrest showed slightly lower EMP counts. These results indicate a potential protective effect of statins on the endothelium during and after ischemia and reperfusion and encourage further investigation of the effect of statin treatment in post-resuscitation care.

Finally, in a smaller population, we were able to detect elevated numbers of EPC in patients on the second day after CPR as an indicator of the early onset of endothelial repair. EPC-mediated vascular repair has been shown to be associated with normalization of endothelial function and restoration of blood flow at the site of injury \[[@B21]\]. These circulating cells are capable of endothelial differentiation and homing to ischemic tissues \[[@B20]\]. EPCs are considered to originate from hematopoietic stem cells, which are positive for CD34 and VEGF-R2 and immature marker protein CD133 \[[@B40]\]. CD34+ blood cell counts are widely used to obtain \'mobilized\' hematopoietic stem/progenitor cells from peripheral blood \[[@B41]\]. Catecholamines are known to induce angiogenesis in tumor tissues \[[@B42]\] and dopamine has been shown to mobilize EPCs from the bone marrow during tumor growth \[[@B43]\]. Nevertheless, norepinephrine failed to increase CD34+ levels in heart failure patients \[[@B44]\]. In the EPC study group, all CPR patients received vasopressors such as norepinephrine and epinephrine but none of them received dopamine. Moreover, a small control group of critically ill patients at our ICU, who did not undergo CPR but received vasopressors and mechanical ventilation, showed no elevation of EPCs (data not shown). However, we cannot exclude the possibility of any influence of catecholamines or ICU procedures administered.

A limitation of the present study is its observatory design. Further experimental studies could allow a more detailed investigation of causes and effects of endothelial damage in post-resuscitation disease. Moreover, experimental studies would allow the assessment of possible therapeutic interventions. In the current study, the number of patients was rather small, particularly in the EPC study. However, the described effects are overwhelming and obtain clear statistical significance.

Conclusions
===========

In this study we provide evidence for an endothelial injury occurring in patients after CPR. The obtained data suggest a two-step process: The early stage during and directly after CPR is prevailed by severe endothelial damage. Within the following 24 hours, inflammation and endothelial repair are taking place. These results could be the basis for further interventional studies with the aim of developing new therapeutic and prognostic strategies in post-resuscitation care. As a perspective, endothelial protection (e.g. statins), anti-inflammatory drugs (e.g. corticosteroids), as well as regenerative therapies (e.g. growth factors) could be promising future therapeutic strategies in the early phases after CPR.

Key messages
============

• Patients after successful CPR show an early and severe endothelial injury.

• Endothelial microparticles, as a sign of endothelial inflammation, rise within the first 24 hours after ROSC.

• On the second day after successful CPR, patients present elevated markers of endothelial repair.
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